NWAM LLC’s Intellia Therapeutics NTLA Stock Holding History

NWAM LLC’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Hold	19,540	–	–	0.02%	536
2026 Q1	$251K	Hold	19,540	–	–	0.01%	545
2025 Q4	$273K	Buy	19,540 +9,040	+86%	+$124K	0.02%	523
2025 Q3	$294K	Buy	+10,500	New	+$129K	0.02%	524

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

NWAM LLC's NTLA Position: Q2 2026 in Review

NWAM LLC held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 19,540 shares worth $331K. The position accounts for 0.02% of the portfolio, ranked #536.

NWAM LLC first reported a position in NTLA in Q3 2025 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

NWAM LLC held 19,540 shares of Intellia Therapeutics worth $331K as of Q2 2026.
NWAM LLC left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 0.02% of NWAM LLC's portfolio in Q2 2026, its #536 holding.
NWAM LLC first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 4 quarters since.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on NWAM LLC's 13F filing for Q2 2026, filed 23 Jul 2026.